Rotarix Articles
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
Europe’s CHMP gives negative opinion for Merck KGaA’ cladribine in multiple sclerosis; backs Sanofi Pasteur MSD’s RotaTeq and GSK’s Rotarix
24 September 2010
US Coalition for Vaccine Safety calls on FDA to immediately suspend all contaminated rotavirus vaccines
11 May 2010
US FDA recommends temporary suspension of GlaxoSmithKline’s Rotarix due to extraneous virus
23 March 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
Celldex gets $10M milestone
13 October 2008
Stock Commentary - Europe - week to April 7, 2008
14 April 2008
US FDA approves GSK's Rotarix
14 April 2008
US FDA to decide on approving GSK's Rotarix
25 February 2008
FDA panel recommends GSK's rotavirus vacc
25 February 2008
Rotarix provides broad protection in EU trial
3 December 2007
US FDA accepts GSK's Rotarix BLA for review
20 August 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Rotarix nominated for prestigious Prix Galien
2 October 2006
GSK
15 May 2006
Avant brings forward $40M Rotarix milestone payment
20 March 2006
GSK's Rotarix vaccine is "highly effective"
16 January 2006
GSK's Rotarix could "lower EU rotavirus burden 89%"
12 September 2005
S-A leapfrogs USA/EU for malaria drug
27 June 2005
GSK's Rotarix effective in children under two
30 May 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
GSK pays Avant $2M as Rotarix MAA accepted
17 January 2005
AVANT demands Berlin stock exchange de-listing
2 August 2004
GSK's Rotarix gets first OK in Mexico
19 July 2004
Showing 1-38 of 38 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
